20 February 2025 - Now approved, seladelpar can provide an important treatment option for people living with the rare liver Disease in the European Economic Area.

Gilead Sciences today announced that the European Commission has granted conditional marketing authorisation for seladelpar for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid alone, or as monotherapy in those unable to tolerate ursodeoxycholic acid.

Read Gilead press release